Disease burden at your fingertips

Page 1 of the report shows that a dominant DNA sequence or sequences were identified from the submitted sample.

A more detailed description of the results for this sample can be found in the “Results Summary” section.

A summary of the criteria used to determine which DNA sequences are dominant and thus can be followed as markers of malignancy is provided at the bottom of the page for reference.

Subsequent pages of the report show detailed information relating to the sample, including the actual rearranged DNA nucleotide sequence or sequences identified, the sample collection date, the receptor locus in which each dominant sequence was found, the specimen type analyzed, the frequency of the dominant sequence as a fraction of the total nucleated cells assessed, and the total number of cells carrying the rearranged DNA sequence.

The final page of the report provides more details on the immune repertoire of the analyzed sample, including the sample clonality, the number of sequences assessed for each locus, and the number of unique sequences assessed.

The first page of the IGHV report shows if IGHV is mutated or unmutated.

A more detailed description of the results for this sample can be found in the “Results Summary” section.

A summary of the criteria used to determine which immunoglobulin heavy chain (IgH) sequences are dominant is provided at the bottom of the page for reference.

In this sample, residual disease was detected by clonoSEQ. This is indicated by the “plus” sign as well as the language stating “Residual Sequences Detected” in the blue box on page 1 of the report.

Further down the page, the Results Summary states the actual number of sequences observed by the assay and the total number of nucleated cells assessed in the sample.

In the bottom third of the page, a chart provides a longitudinal view of the sample-level MRD result for the current sample as well as for past samples sent for clonoSEQ testing for this patient.

Subsequent pages of the report show detailed information relating to the current and previous samples, including the actual rearranged DNA nucleotide sequence or sequences identified, sample collection dates, the receptor locus in which each dominant sequence was found, the specimen type analyzed, the estimated sequence abundance (ie, the number of residual clonal cells per million nucleated cells), and the 95% confidence interval for each MRD result.

A blue bar will be placed next to one of the sequences listed on this page to indicate that it is the sequence determining the MRD result for the current sample.

Subsequent pages of the report display the sequence-level information in a chart format. This “sequence-level MRD” chart provides a longitudinal view of results for each individual tracked sequence.

The appendix provides more details on the immune repertoire of the analyzed sample, including the sample clonality, the number of sequences assessed for each locus, and the number of unique sequences assessed.

In this example, residual disease was detected in a plasma sample. This is indicated by the “plus” sign as well as the language stating “Residual Sequence(s) Detected” in the blue box on page 1 of the report (1). Also in the blue box, the report provides a quantitative assessment of the number of sequences detected per milliliter (mL) of plasma evaluated.

Number of residual sequences observed out of total volume (in mL) of plasma assessed.

Chart showing sample-level MRD results over time.

Subsequent pages of the report show detailed information relating to the current and previous samples including the actual rearranged DNA nucleotide sequence(s) identified, sample collection dates, the receptor locus on which each dominant sequence was found, the specimen type analyzed, and the number of dominant sequences identified in each sample that has been evaluated (4).

A blue bar (5) will be placed next to one of the sequences listed on this page to indicate that it is the sequence determining the MRD result for the current sample. The sequence(s) that determined the previous samples are noted with a blue check mark.

Subsequent pages of the report display the sequence-level information in a chart format (6). This “sequence-level MRD” chart provides a longitudinal view of results for each individual tracked sequence, for the current sample as well as for past ctDNA samples sent for clonoSEQ testing for this patient. Similar to the “sample-level” chart, the sequence-level chart includes a point on the chart for each ctDNA test with a corresponding test date, but on this chart, each individual sequence is displayed separately.

ctDNA, circulating tumor DNA.

The Appendix provides additional details on the immune repertoire of the analyzed sample, including the sample clonality, the number of sequences assessed for each locus, and the number of unique sequences assessed.